基本信息
浏览量:0
职业迁徙
个人简介
Degrees, Temple University School of Medicine / MD (1978)。 Residencies, Temple University School of Medicine / Internal Medicine (1982)。 Fellowships, Johns Hopkins University School of Medicine / Oncology (1987)。
Certifications:
American Board of Internal Medicine / Internal Medicine (1981);
American Board of Internal Medicine / Medical Oncology (1987)。
The overall goal of Dr. Jones' research is to better understand the biology of normal and abnormal hematopoiesis, with an eye to improving the treatment of blood disorders by translating promising findings to the clinic. A primary area of focus is to identification and biologic characterization of cancer stem cells. It appears that, for most cancers, only a small fraction of the cancer cells retains the capacity to self-renew and proliferate. These characterize the disease. In many tumors, cancer stem cells and their differentiated progeny appear to have markedly different biologic characteristics. Characterizing cancer stem cells has particular relevance for targeted anti-cancer therapies. Therapies that target mature tumor cells may lead to clinical improvement, but are unlikely to be curative unless cancer stem cells are also targeted. Alternatively, relevant targets unique to the rare cancer stem cells may be missed of clinical activity is judged soley by criteria that reflect the effects of treatment on the bulk of the cancer. Thus, understanding the biology of cancer stem cells, especially in relation to their differentiated progeny, is essential for developing effective anticancer treatments. One cancer stem cell specific therapy that appears promising is differentiation therapy. Although self-renewal and differentiation are effectively coupled in normal stem cells, all cancer stem cells show some degree of differentiation block. Re-establishing the differentiation program in cancer stem cells should promote their maturation, leading to a loss of self-renewal capacity.
Selected Publications:
Aksentijevich, I.; Jones, R.J.; Ambinder, R.F.; Garrett-Mayer, E.; Flinn, I.W. Clinical outcome following autologous and allogeneic blood and marrow transplantation for relapsed diffuse large-cell non-Hodgkin''s lymphoma. Biol Blood Marrow Transplant. 2006 Sep;12(9):965-972.
Bolanos-Meade, J.; Hartley, E.; Jones, R.J. Long-term follow-up of allogeneic marrow transplantation for acute myelogenous leukemia after treatment with busulfan and cyclophosphamide. Biol Blood Marrow Transplant. 2006 Mar;12(3):366-367.
Brodsky, R.A.; Jones, R.J. Aplastic Anemia. In: Rose, N.R.; Mackay, I.R., editors. 4th ed, The Autoimmune Diseases. Philadelphia, PA: Elsevier; 2006.
Huff, C.A.; Fuchs, E.J.; Smith, B.D.; Blackford, A.; Garrett-Mayer, E.; Brodsky, R.A.; Flinn, I.W.; Ambinder, R.F.; Borrello, I.M.; Matsui, W.H.; Vogelsang, G.B.; Griffin, C.A.; Luznik, L.; Jones, R.J. Graft-versus-host reactions and the effectiveness of donor lymphocyte infusions. Biol Blood Marrow Transplant. 2006 Apr;12(4):414-421.
Huff, C.A.; Matsui, W.; Smith, B.D.; Jones, R.J. The paradox of response and survival in cancer therapeutics. Blood. 2006 Jan 15;107(2):431-434.
Huff, C.A.; Matsui, W.H.; Douglas Smith, B.; Jones, R.J. Strategies to eliminate cancer stem cells: clinical implications. Eur J Cancer. 2006 Jun;42(9):1293-1297.
Certifications:
American Board of Internal Medicine / Internal Medicine (1981);
American Board of Internal Medicine / Medical Oncology (1987)。
The overall goal of Dr. Jones' research is to better understand the biology of normal and abnormal hematopoiesis, with an eye to improving the treatment of blood disorders by translating promising findings to the clinic. A primary area of focus is to identification and biologic characterization of cancer stem cells. It appears that, for most cancers, only a small fraction of the cancer cells retains the capacity to self-renew and proliferate. These characterize the disease. In many tumors, cancer stem cells and their differentiated progeny appear to have markedly different biologic characteristics. Characterizing cancer stem cells has particular relevance for targeted anti-cancer therapies. Therapies that target mature tumor cells may lead to clinical improvement, but are unlikely to be curative unless cancer stem cells are also targeted. Alternatively, relevant targets unique to the rare cancer stem cells may be missed of clinical activity is judged soley by criteria that reflect the effects of treatment on the bulk of the cancer. Thus, understanding the biology of cancer stem cells, especially in relation to their differentiated progeny, is essential for developing effective anticancer treatments. One cancer stem cell specific therapy that appears promising is differentiation therapy. Although self-renewal and differentiation are effectively coupled in normal stem cells, all cancer stem cells show some degree of differentiation block. Re-establishing the differentiation program in cancer stem cells should promote their maturation, leading to a loss of self-renewal capacity.
Selected Publications:
Aksentijevich, I.; Jones, R.J.; Ambinder, R.F.; Garrett-Mayer, E.; Flinn, I.W. Clinical outcome following autologous and allogeneic blood and marrow transplantation for relapsed diffuse large-cell non-Hodgkin''s lymphoma. Biol Blood Marrow Transplant. 2006 Sep;12(9):965-972.
Bolanos-Meade, J.; Hartley, E.; Jones, R.J. Long-term follow-up of allogeneic marrow transplantation for acute myelogenous leukemia after treatment with busulfan and cyclophosphamide. Biol Blood Marrow Transplant. 2006 Mar;12(3):366-367.
Brodsky, R.A.; Jones, R.J. Aplastic Anemia. In: Rose, N.R.; Mackay, I.R., editors. 4th ed, The Autoimmune Diseases. Philadelphia, PA: Elsevier; 2006.
Huff, C.A.; Fuchs, E.J.; Smith, B.D.; Blackford, A.; Garrett-Mayer, E.; Brodsky, R.A.; Flinn, I.W.; Ambinder, R.F.; Borrello, I.M.; Matsui, W.H.; Vogelsang, G.B.; Griffin, C.A.; Luznik, L.; Jones, R.J. Graft-versus-host reactions and the effectiveness of donor lymphocyte infusions. Biol Blood Marrow Transplant. 2006 Apr;12(4):414-421.
Huff, C.A.; Matsui, W.; Smith, B.D.; Jones, R.J. The paradox of response and survival in cancer therapeutics. Blood. 2006 Jan 15;107(2):431-434.
Huff, C.A.; Matsui, W.H.; Douglas Smith, B.; Jones, R.J. Strategies to eliminate cancer stem cells: clinical implications. Eur J Cancer. 2006 Jun;42(9):1293-1297.
研究兴趣
论文共 805 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Jonaphine Rae Mata,Marianna Zahurak, Natalie Rosen, Amy E. DeZern,Richard J Jones,Alexander J Ambinder
Transplantation and Cellular Therapyno. S3 (2024): e7363304-e7363304
Haematologicano. 3 (2024): 948-952
HAEMATOLOGICAno. 2 (2024): 657-660
Bone Marrow Transplantationno. 3 (2024): 428-430
Research square (2024)
Blood reviews (2023): 101096-101096
J. Kyle Bruner,Hayley S. Ma,Li Li, Alice Can Ran Qin,Michelle A. Rudek,Richard J. Jones,Mark J. Levis,Keith W. Pratz,Christine A. Pratilas,Donald Small
crossref(2023)
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn